Pembrolizumab (MK-3475) versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.

被引：4
|
作者：
Ohtsu, Atsushi
Tabernero, Josep
Bang, Yung-Jue
Fuchs, Charles S.
Sun, Linda
Wang, Zhen
Csiki, Ildiko
Koshiji, Minori
Van Cutsem, Eric
机构：
[1] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Seoul Natl Univ Hosp, Seoul 110744, South Korea
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Merck & Co Inc, Kenilworth, NJ USA
[6] MSD China, Beijing, Peoples R China
[7] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期
关键词：
D O I：
10.1200/jco.2016.34.4_suppl.tps183
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS183
引用
收藏
页数：1
相关论文
共 50 条
  • [31] KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.
    Bellmunt, Joaquim
    Sonpavde, Guru
    De Wit, Ronald
    Choueiri, Toni K.
    Siefker-Radtke, Arlene O.
    Plimack, Elizabeth R.
    Lewis, Nicole M.
    Brown, Holly
    Mai, Yabing
    Gause, Christine K.
    Kaufman, David Ross
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [32] Fruquintinib combined with sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): A phase II, single-arm, prospective study.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 332 - 332
  • [33] Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma
    Schlintl, Verena
    Huemer, Florian
    Greil, Richard
    Weiss, Lukas
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 12 (02) : 906 - 909
  • [34] A phase II study of MK-2206, an allosteric inhibitor of AKT as second-line therapy for advanced gastric and gastroesophageal junction (GEJ) cancer: A SWOG Cooperative Group trial (S1005).
    Ramanathan, Ramesh K.
    McDonough, Shannon L.
    Kennecke, Hagen F.
    Iqbal, Syma
    Baranda, Joaquina Celebre
    Seery, Tara Elisabeth
    Lim, Howard John
    Hezel, Aram F.
    Vaccaro, Gina M.
    Blanke, Charles David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [35] A phase II study of fruquintinib plus sintilimab as a second-line therapy for advanced gastric and gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results.
    Jin, Min
    Yang, Shengli
    Liu, Junli
    Zhang, Jieying
    Zhao, Lei
    Yu, Dandan
    Lin, Zhenyu
    Li, Pindong
    Wang, Jing
    Xue, Jun
    Ma, Hong
    Hu, Jianli
    Zhang, Tao
    Liu, Hongli
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 407 - 407
  • [36] Randomized phase II study of PEP02, irinotecan, or docetaxel as a second-line therapy in gastric or gastroesophageal junction adenocarcinoma
    Cunningham, D.
    Park, S.
    Kang, Y.
    Chao, Y.
    Chen, L.
    Rees, C.
    Lim, H.
    Tabernero, J.
    Yeh, G.
    De Gramont, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [37] Study on the efficacy and safety of sintilimab combined with nab-paclitaxel as second-line treatment for advanced or metastatic gastric cancer (GC)/ gastroesophageal junction (GEJ) cancer.
    Wang, Jianzheng
    He, Yunduan
    Zhang, Baiwen
    Cheng, Xiaojiao
    Li, Qingli
    Lv, Huifang
    Nie, Caiyun
    Chen, Beibei
    Xu, Weifeng
    Zhao, Jing
    Tu, Shuiping
    Chen, Xiaobing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16016 - E16016
  • [38] Association between gene expression signatures and clinical outcomes of pembrolizumab versus paclitaxel in advanced gastric cancer: exploratory analysis from the randomized, controlled, phase III KEYNOTE-061 trial
    Shitara, Kohei
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Caglevic, Christian
    Olesinski, Tomasz
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    McDermott, Raymond S.
    Mansoor, Wasat
    Wainberg, Zev A.
    Shih, Chie-Schin
    Kobie, Julie
    Nebozhyn, Michael
    Cristescu, Razvan
    Cao, Z. Alexander
    Loboda, Andrey
    Ozguroglu, Mustafa
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (06)
  • [39] A randomized, double-blind, phase III study of pembrolizumab plus chemotherapy as first-line therapy in patients with HER2-negative, advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: KEYNOTE-859
    Qin, S.
    Tabernero, J.
    van Cutsem, E.
    Fuchs, C. S.
    Janjigian, Y. Y.
    Bhagia, P.
    Li, K.
    Adelberg, D.
    Bang, Y-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1316 - S1317
  • [40] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
12345